# Drug Target Research Platforms - Competitive Landscape Analysis

## Executive Summary

This report analyzes the competitive landscape of drug target research platforms and bioinformatics analysis tools, focusing on output formats, reproducibility mechanisms, evidence packaging, and regulatory compliance standards. The analysis covers six major platforms and identifies key differentiators for building a competitive drug target assessment system.

---

## 1. OpenTargets Platform

### Overview
OpenTargets is a comprehensive drug target identification and validation platform developed by a consortium including EMBL-EBI, Genentech, GSK, MSD, Pfizer, Sanofi, and Wellcome Sanger Institute. It provides systematic evidence integration for target-disease associations.

### Output Formats & Deliverables

**API & Data Access:**
- **GraphQL API** (v4) - Primary programmatic access method
- **REST API** - Legacy support available
- **Bulk Downloads** - Pre-computed datasets available in multiple formats

**Downloadable Formats:**
- **JSON** - Evidence objects following OpenTargets JSON Schema (versioned schema definitions)
- **TSV/CSV** - Tabular data exports for associations and evidence
- **Parquet** - Columnar data format for large-scale analysis (ETL pipeline outputs)
- **API Response** - JSON responses from GraphQL queries (v4 API)

**GraphQL API Schema:**
- Queries: targets, diseases, drugs, associations, search
- Data sources: ClickHouse + Elasticsearch 7.2
- Evidence objects: Typed with JSON Schema validation
- Association scores: Weighted combination across data sources

**Evidence Packages:**
- Target-disease association scores with evidence breakdowns
- Data source-specific evidence strings (genetics, genomics, transcriptomics, literature, drugs, animal models)
- Druggability assessments
- Safety profiles and adverse event data (OpenFDA integration)

**Reproducibility Features:**
- Versioned data releases with release notes
- Evidence source tracking with provenance metadata
- JSON Schema definitions for all data types
- Curation repository for manual annotations
- ETL pipeline code publicly available

**Source Data References:**
- Systematic literature citations (Europe PMC integration)
- Database accession numbers for all evidence sources
- Publication DOIs and PMIDs
- Data provider timestamps and version information

### Key Differentiators
- **Multi-source evidence integration** - Combines 20+ data sources
- **Quantitative scoring** - Statistical association scores with confidence intervals
- **Target-disease-drug triad** - Integrated view of therapeutic landscape
- **Open source** - Full codebase available on GitHub
- **Enterprise consortium** - Backed by major pharma companies

### Limitations
- No built-in PDF report generation
- Limited visualization export options
- Requires technical expertise for API usage
- No automated regulatory-ready report generation

---

## 2. cBioPortal

### Overview
cBioPortal is a leading cancer genomics visualization and analysis platform, originally developed at Memorial Sloan Kettering Cancer Center. It focuses on large-scale cancer genomics datasets including TCGA, ICGC, and institutional datasets.

### Output Formats & Deliverables

**Data Export Options:**
- **ZIP Archives** - Complete study datasets downloadable from Datasets Page
- **TSV Files** - Tab-separated values for all data types
- **R Data Objects** - Via cBioPortalData Bioconductor package (MultiAssayExperiment)
- **Python DataFrames** - Via cbio_py client or bravado Swagger client
- **REST API** - Swagger/OpenAPI documented endpoints (v3 API)

**API Client Ecosystem:**
- **R**: cBioPortalData (Bioconductor), cbioportalR (tidyverse-compatible), rapiclient
- **Python**: bravado (Swagger), cbio_py, gget
- **CLI**: curl-based access
- **Authentication**: Token-based for private instances

**Supported Data Types:**
- Mutation data (MAF format)
- Copy number alterations (discrete and continuous)
- Expression data (RNA-seq, microarray)
- Methylation data
- Protein expression (RPPA)
- Clinical data (patient and sample attributes)
- Structural variants and fusions
- Timeline data
- Gene panel data
- Generic assay data

**Visualization Outputs:**
- OncoPrint plots (interactive)
- Survival curves
- Scatter plots
- Heatmaps
- Box plots
- Network views
- **Export formats**: PNG, SVG for static images
- **Interactive**: HTML-based interactive plots

**Reproducibility Features:**
- Data loading validation tools
- Standardized file format specifications
- Study metadata with citation information
- Version-controlled datahub repository
- Seed database for local instance deployment

**Source Data References:**
- PubMed IDs (PMIDs) for associated publications
- Study citation information
- Data source attribution
- TCGA/ICGC study identifiers

### Key Differentiators
- **Cancer-focused** - Deep specialization in oncology genomics
- **Large-scale datasets** - Handles TCGA, ICGC, institutional data
- **Interactive visualization** - Rich web-based exploration tools
- **Multi-study analysis** - Cross-study comparison capabilities
- **Active community** - Extensive documentation and tutorials

### Limitations
- Cancer-specific (not general drug targets)
- No automated report generation
- Limited export to publication-ready formats
- No built-in regulatory compliance features

---

## 3. GEPIA2 (Gene Expression Profiling Interactive Analysis)

### Overview
GEPIA2 is a web-based tool for gene expression analysis using TCGA and GTEx data, developed by Peking University. It focuses on differential expression analysis, survival analysis, and correlation analysis.

### Output Formats & Deliverables

**Analysis Outputs:**
- **Interactive Plots** - Box plots, survival curves, scatter plots, violin plots
- **Static Exports** - PNG, SVG, PDF formats for figures
- **Tabular Results** - CSV/TSV download of statistical results
- **Gene Expression Data** - Normalized expression values

**Supported Analyses:**
- Differential expression analysis (tumor vs normal)
- Survival analysis (Kaplan-Meier curves)
- Gene correlation analysis
- Dimensionality reduction (PCA, t-SNE)
- Similar gene detection
- Expression profiling by cancer stage

**Data Sources:**
- TCGA (The Cancer Genome Atlas)
- GTEx (Genotype-Tissue Expression)
- TARGET (Therapeutically Applicable Research to Generate Effective Treatments)

**Reproducibility Features:**
- Standardized TCGA/GTEx data processing pipelines
- Statistical methodology documentation
- Cutoff parameters for survival analysis
- Batch effect correction methods

**Key Differentiators:**
- **User-friendly interface** - No programming required
- **Fast analysis** - Pre-computed for TCGA/GTEx data
- **Comprehensive survival analysis** - Multiple cutoff methods
- **Pan-cancer analysis** - 33 cancer types from TCGA

### Limitations
- Limited to expression data only
- No drug target-specific features
- No API access
- Limited customization options
- No automated report generation
- No regulatory compliance features

---

## 4. UALCAN (University of Alabama at Birmingham Cancer data analysis Portal)

### Overview
UALCAN is a comprehensive web resource for analyzing cancer OMICS data, particularly focused on TCGA gene expression data and survival analysis.

### Output Formats & Deliverables

**Analysis Outputs:**
- **Expression Plots** - Box plots, bar charts with statistical significance
- **Survival Curves** - Kaplan-Meier plots with hazard ratios
- **Heatmaps** - Gene expression heatmaps across cancer types
- **Static Downloads** - PNG, PDF, SVG for all visualizations
- **Tabular Data** - CSV downloads for expression data and statistics

**Supported Analyses:**
- Gene expression analysis (tumor vs normal, stage-wise)
- Patient survival analysis
- Correlation analysis
- Promoter methylation analysis
- miRNA expression analysis
- Protein expression analysis (CPTAC)
- Pan-cancer expression analysis
- Clinical feature analysis

**Data Sources:**
- TCGA (RNA-seq, miRNA-seq, methylation)
- CPTAC (Clinical Proteomic Tumor Analysis Consortium)
- Cell line data (CCLE - Cancer Cell Line Encyclopedia)

**Reproducibility Features:**
- Standardized TCGA data processing
- Statistical test documentation (t-test, ANOVA, log-rank)
- Sample size information
- Confidence intervals for survival analysis
- Multiple testing correction methods

**Key Differentiators:**
- **Clinical integration** - Links expression to clinical outcomes
- **Multi-omics** - RNA, miRNA, methylation, protein
- **Publication-ready** - High-quality figures
- **CPTAC integration** - Proteomics validation

### Limitations
- Web-only interface (limited API)
- TCGA-centric (limited external validation)
- No automated report generation
- No regulatory compliance features
- Limited to cancer applications

---

## 5. TIMER2.0 (Tumor Immune Estimation Resource)

### Overview
TIMER2.0 is a comprehensive resource for analyzing tumor-immune infiltrations across 33 cancer types from TCGA, providing systematic analysis of immune cell infiltration in the tumor microenvironment.

### Output Formats & Deliverables

**Analysis Outputs:**
- **Immune Cell Abundance Estimates** - Scores for 6 immune cell types (B cells, CD4+ T cells, CD8+ T cells, Neutrophils, Macrophages, Dendritic cells)
- **Correlation Plots** - Scatter plots showing gene-immune cell correlations
- **Survival Plots** - Kaplan-Meier curves stratified by immune infiltration
- **Box Plots** - Expression comparisons across immune subtypes
- **Heatmaps** - Pan-cancer immune infiltration patterns
- **Static Exports** - PNG, PDF, SVG formats

**Supported Analyses:**
- Immune infiltration estimation (multiple algorithms)
- Gene-immune cell correlation analysis
- Survival analysis by immune infiltration
- Differential expression by immune subtype
- Somatic mutation-immune correlation
- Clinical outcome prediction

**Estimation Methods:**
- TIMER (original algorithm)
- CIBERSORT
- CIBERSORT-ABS
- QUANTISEQ
- MCPCOUNTER
- XCELL
- EPIC

**Reproducibility Features:**
- Multiple estimation algorithm comparison
- TCGA standardized data processing
- Statistical methodology documentation
- Algorithm validation studies
- Cross-method consistency metrics

**Key Differentiators:**
- **Immune focus** - Specialized in tumor immunology
- **Multi-algorithm** - 7 immune estimation methods
- **Pan-cancer coverage** - 33 TCGA cancer types
- **Clinical relevance** - Links immune infiltration to outcomes

### Limitations
- Web-only interface
- Limited to immune infiltration analysis
- No API for programmatic access
- No automated report generation
- No regulatory compliance features
- TCGA-dependent

---

## 6. PharmGKB (Pharmacogenomics Knowledge Base)

### Overview
PharmGKB is a comprehensive pharmacogenomics knowledge base that curates information about the impact of genetic variation on drug response, maintained by Stanford University.

### Output Formats & Deliverables

**Knowledge Outputs:**
- **Drug Pathways** - Visual pathway diagrams (SVG, PNG)
- **Gene Reports** - Comprehensive gene annotations
- **Drug Reports** - Drug-label associations
- **Disease Reports** - Pharmacogenomic disease annotations
- **Variant Reports** - Clinical annotations for genetic variants
- **Clinical Annotations** - Evidence-based genotype-phenotype relationships

**Downloadable Data:**
- **Flat Files** - TSV downloads for genes, drugs, diseases, variants
- **API Access** - RESTful API with JSON responses (Swagger documentation at api.pharmgkb.org/swagger)
- **Bulk Downloads** - Complete dataset exports
- **R Package** - pgxRpi for programmatic access

**API Endpoints (Key):**
- `GET /v1/clinicalAnnotation` - Pharmacogenomic annotations
- Query parameters: `location.genes.symbol`, `relatedChemicals.name`, `levelOfEvidence.term`, etc.
- Evidence levels: 1A, 1B, 2A, 2B, 3, 4 (systematic classification)
- Response format: JSON with nested gene/variant/drug relationships

**Evidence Packages:**
- Clinical annotation levels (1A, 1B, 2A, 2B, 3, 4)
- Guideline annotations (CPIC, DPWG, FDA)
- FDA drug label annotations
- Clinical trial pharmacogenomic information
- Literature citations with evidence levels

**Reproducibility Features:**
- Curated evidence with source attribution
- Evidence level classification system
- Guideline source tracking
- Literature citation with PMIDs
- Version-controlled knowledge base
- Regular update cycles with change logs

**Regulatory Compliance:**
- **FDA Alignment** - Maps to FDA pharmacogenomic guidance
- **CPIC Guidelines** - Clinical Pharmacogenetics Implementation Consortium
- **DPWG Guidelines** - Dutch Pharmacogenetics Working Group
- **Drug Labels** - FDA-approved pharmacogenomic information

**Key Differentiators:**
- **Clinical grade** - Curated for clinical decision support
- **Guideline integration** - CPIC, DPWG, FDA alignment
- **Evidence hierarchy** - Systematic evidence classification
- **Regulatory ready** - Supports regulatory submissions
- **Pharmacogenomics focus** - Specialized expertise

### Limitations
- Pharmacogenomics-specific (not general drug targets)
- Limited visualization capabilities
- No automated report generation
- Requires interpretation expertise

---

## 7. Alvessa Agent (Emerging Competitor)

### Overview
Alvessa is a multi-agent AI framework for genomics and drug target assessment that provides evidence-grounded answers with statement-level verification against database records.

### Output Formats & Deliverables

**Analysis Outputs:**
- **JSON Pipeline State** - Serialized analysis state (`demo.json`)
- **Human-Readable Reports** - Text answers with citations (`demo.txt`)
- **Interactive UI** - Web interface with citation links
- **Verification Feedback** - Per-statement evidence verification

**Integrated Data Sources:**
- Variant annotation (dbSNP, ClinVar, AlphaMissense, Sei, ExpectoSC)
- Gene annotation (GENCODE, UniProt, Alliance of Genome Resources, OMIM)
- Pathways & interactions (Reactome, MSigDB, BioGRID, Gene Ontology, IntAct)
- Drug & druggability (ChEMBL, DrugCentral, CysDB, OpenTargets)
- Protein structure (AlphaFold, FPocket, FreeSASA, IUPred3, DisProt, BioLiP2)
- Disease associations (GWAS Catalog, OpenTargets, ClinVar)

**Reproducibility Features:**
- Statement-level verification against database records
- Inline citations with source links
- Verification feedback for unsupported claims
- Serialized pipeline state for reproducibility
- Tool orchestration documentation

**Key Differentiators:**
- **AI-powered** - Multi-agent orchestration
- **Evidence grounding** - Statement-level verification
- **Hallucination prevention** - Database record validation
- **Integrated tooling** - 30+ database integrations

### Limitations
- Early-stage (research project)
- Limited output format options
- No regulatory compliance features
- No automated PDF report generation
- Requires local database setup (45GB)

---

## 8. ByO Target Platform (Emerging Competitor - Multi-Agent Approach)

### Overview
ByO Target Platform (Target Validation Assistant) is a Korean-developed multi-agent AI platform for evidence-based target validation in early-stage drug discovery. It uses a Retriever → Extractor → Synthesizer pipeline to automatically collect literature, extract structured evidence, and generate target dossiers.

### Output Formats & Deliverables

**Report Outputs:**
- **Target Dossier (PDF)** - Structured report using ReportLab (A4 format)
- **Markdown Reports** - Machine-readable dossier format
- **JSON Pipeline State** - Serialized analysis state
- **Interactive Web Dashboard** - React-based visualization

**Target Dossier Structure:**
1. **Target Profile** - Gene/protein identification and characterization
2. **Key Claims** - Evidence-based assertions about target validity
3. **Evidence Level Summary** - Classification by evidence type (in vitro / in vivo / clinical)
4. **Risk Signals** - Potential concerns and limitations
5. **Next Validation Steps** - Recommended follow-up experiments

**Evidence Extraction Features:**
- Claim filtering and classification
- Outcome claim building from literature
- Evidence type categorization (in vitro, in vivo, clinical)
- Citation tracking with PMID references

**Technical Stack:**
- **AI Engine**: Upstage Solar LLM (solar-pro2)
- **Embeddings**: Upstage Solar Embedding (solar-embedding-1-large)
- **Vector DB**: ChromaDB
- **LLM Framework**: LangChain
- **Frontend**: React + Vite + Tailwind CSS
- **Backend**: FastAPI + PostgreSQL

**Reproducibility Features:**
- Session-based analysis tracking
- Serialized pipeline state preservation
- Citation verification with PMIDs
- Multi-agent audit trail

**Key Differentiators:**
- **Multi-agent pipeline** - Automated Retriever → Extractor → Synthesizer workflow
- **Target Dossier format** - Structured evidence package for decision-making
- **Literature automation** - PubMed and ArXiv integration
- **Evidence hierarchy** - Systematic classification by evidence strength
- **PDF report generation** - Automated ReportLab-based output

### Limitations
- Early-stage project (academic)
- Limited database integrations (primarily literature-based)
- No regulatory compliance features
- Korean-language documentation
- Limited validation data sources

---

## 9. Standard Formats for Research Reports

### Regulatory & Reporting Standards

#### REMARK (REporting recommendations for tumour MARKer prognostic studies)
- **Purpose**: Guidelines for reporting tumor marker prognostic studies
- **Key Requirements**:
  - Study objectives and hypotheses
  - Patient population and selection criteria
  - Specimen characteristics and handling
  - Assay methods and scoring
  - Study design and statistical methods
  - Results with confidence intervals
  - Discussion of limitations
- **Output Format**: Structured manuscript sections, typically PDF

#### STROBE (Strengthening the Reporting of OBservational studies in Epidemiology)
- **Purpose**: Guidelines for observational study reporting
- **Key Requirements**:
  - Title, abstract, introduction
  - Methods (study design, setting, participants, variables, data sources, bias, study size, statistical methods)
  - Results (descriptive data, outcome data, main results, other analyses)
  - Discussion (limitations, generalizability, interpretation)
- **Output Format**: Structured manuscript, typically PDF

#### MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments)
- **Purpose**: Guidelines for qPCR experiment reporting
- **Key Requirements**:
  - Experimental design
  - Sample information
  - Nucleic acid extraction
  - Reverse transcription
  - qPCR target information
  - qPCR oligonucleotides
  - qPCR protocol
  - qPCR validation
  - Data analysis
- **Output Format**: Checklist-based reporting, PDF

#### ICH M4 (Common Technical Document)
- **Purpose**: Regulatory submission format for drug applications
- **Key Requirements**:
  - Module 1: Administrative information
  - Module 2: Summaries (Quality Overall Summary, Nonclinical/Clinical Overview)
  - Module 3: Quality (drug substance, drug product)
  - Module 4: Nonclinical Study Reports
  - Module 5: Clinical Study Reports
- **Output Format**: PDF with structured modules

### Pharma/Biotech Target Assessment Standards

#### Target Identification Study Deliverables
1. **Target Overview Report**
   - Gene/protein identification and aliases
   - Expression pattern analysis
   - Subcellular localization
   - Protein family classification
   - Druggability assessment

2. **Genetic Evidence Package**
   - GWAS associations
   - Rare variant analyses
   - Mendelian disease associations
   - Functional genomics data (CRISPR screens)

3. **Transcriptomic Evidence Package**
   - Differential expression analysis
   - Tissue expression profiles
   - Disease vs. normal comparisons
   - Cell-type specific expression

4. **Proteomic Evidence Package**
   - Protein expression data
   - Post-translational modifications
   - Protein-protein interactions
   - Structural information

5. **Pathway Analysis Report**
   - Biological pathway involvement
   - Network analysis
   - Upstream/downstream relationships
   - Druggable pathway assessment

6. **Safety Assessment**
   - Tissue-specific expression (safety concerns)
   - Genetic knockout phenotypes
   - Ortholog conservation
   - Essential gene status

7. **Competitive Intelligence**
   - Existing drugs targeting pathway
   - Clinical trial landscape
   - Patent analysis
   - Publication trends

#### Regulatory Agency Expectations (FDA/EMA)

**Target Validation Data Package:**
1. **Mechanistic Rationale**
   - Biological plausibility
   - Disease linkage evidence
   - Pathway involvement

2. **Preclinical Evidence**
   - In vitro validation studies
   - Animal model data
   - Biomarker identification
   - Safety pharmacology

3. **Clinical Relevance**
   - Human genetic evidence
   - Expression in disease tissue
   - Correlation with clinical outcomes
   - Druggability assessment

4. **Risk Assessment**
   - On-target toxicity concerns
   - Off-target effects
   - Patient stratification biomarkers
   - Companion diagnostic potential

**FDA-Specific Requirements:**
- IND application target rationale
- Biomarker qualification packages
- Pharmacogenomic data submissions (FDA Guidance)
- Real-world evidence integration
- Patient-focused drug development

**EMA-Specific Requirements:**
- Scientific advice packages
- Adaptive pathways consideration
- PRIME designation support
- Real-world evidence frameworks

---

## 10. Key Gaps & Opportunities

### Common Limitations Across Competitors

1. **No Automated Report Generation**
   - All platforms require manual report compilation
   - No integrated PDF/PUB report generation
   - Limited publication-ready output formats

2. **Limited Regulatory Alignment**
   - No REMARK/STROBE compliance checking
   - No ICH M4 format support
   - No automated regulatory submission packages

3. **Fragmented Evidence Integration**
   - Each platform focuses on specific data types
   - No unified target assessment workflow
   - Manual integration required across platforms

4. **Limited Reproducibility**
   - Most lack version-controlled analysis pipelines
   - Limited provenance tracking
   - No automated audit trails

5. **Poor Export Capabilities**
   - Limited figure export options
   - No standardized report templates
   - No machine-readable evidence packages

### Competitive Opportunities

1. **Unified Target Assessment Platform**
   - Integrate data from all competitors
   - Automated evidence synthesis
   - Single-platform workflow

2. **Regulatory-Ready Output**
   - REMARK/STROBE compliance checking
   - ICH M4 format generation
   - FDA/EMA submission support

3. **AI-Powered Report Generation**
   - Automated PDF/PUB report generation
   - Citation verification and validation
   - Evidence strength assessment

4. **Reproducibility by Design**
   - Version-controlled pipelines
   - Complete audit trails
   - Provenance tracking

5. **Clinical Translation Support**
   - Biomarker identification
   - Patient stratification
   - Companion diagnostic development

---

## 11. Recommendations for SCALE Engine

### Core Differentiators to Build

1. **Automated Evidence Integration**
   - APIs from all major databases (OpenTargets, cBioPortal, PharmGKB, etc.)
   - Standardized evidence scoring
   - Conflict resolution algorithms

2. **Regulatory-Compliant Output**
   - Pre-validated report templates
   - REMARK/STROBE/MIQE checklists
   - FDA/EMA submission packages

3. **Publication-Ready Reports**
   - Automated PDF generation with proper formatting
   - Journal-specific templates
   - Citation management and verification

4. **Reproducibility Framework**
   - Version-controlled analysis pipelines
   - Complete audit trails
   - Automated documentation

5. **AI-Enhanced Analysis**
   - Multi-agent orchestration (like Alvessa)
   - Evidence verification
   - Gap analysis and recommendations

### Technical Architecture Recommendations

1. **Data Layer**
   - Unified API wrapper for all data sources
   - Standardized data models
   - Caching and versioning

2. **Analysis Layer**
   - Modular analysis components
   - Statistical validation
   - Cross-method comparison

3. **Reporting Layer**
   - Template-based report generation
   - Multi-format output (PDF, DOCX, HTML)
   - Regulatory compliance checking

4. **Verification Layer**
   - Evidence strength assessment
   - Citation verification
   - Contradiction detection

---

## Appendix A: Competitor Feature Matrix

| Feature | OpenTargets | cBioPortal | GEPIA2 | UALCAN | TIMER2.0 | PharmGKB | Alvessa | ByO TVA |
|---------|-------------|------------|--------|--------|----------|----------|---------|---------|
| API Access | GraphQL | REST | None | Limited | None | REST | CLI | REST |
| Bulk Downloads | Yes | Yes | Limited | Limited | Limited | Yes | JSON | JSON |
| PDF Reports | No | No | No | No | No | No | No | Yes |
| SVG/PNG Export | No | Yes | Yes | Yes | Yes | Yes | No | No |
| CSV/TSV Data | Yes | Yes | Yes | Yes | Yes | Yes | JSON | JSON |
| JSON API | Yes | Yes | No | No | No | Yes | Yes | Yes |
| Reproducibility | High | High | Medium | Medium | Medium | High | High | Medium |
| Regulatory Focus | Low | Low | Low | Low | Low | High | Low | Low |
| Cancer Focus | Low | High | High | High | High | Low | Low | Low |
| General Targets | High | Low | Low | Low | Low | Low | High | High |
| AI Integration | No | No | No | No | No | No | Yes | Yes |
| Multi-Agent | No | No | No | No | No | No | Yes | Yes |
| Evidence Verification | No | No | No | No | No | Manual | Yes | Yes |
| Target Dossier | No | No | No | No | No | No | No | Yes |

## Appendix B: Data Source Coverage

| Data Type | OpenTargets | cBioPortal | GEPIA2 | UALCAN | TIMER2.0 | PharmGKB |
|-----------|-------------|------------|--------|--------|----------|----------|
| Genomics | Yes | Yes | No | No | No | Yes |
| Transcriptomics | Yes | Yes | Yes | Yes | Yes | No |
| Proteomics | Limited | Yes | No | Yes | No | No |
| Epigenomics | Yes | Yes | No | Yes | No | No |
| Clinical | Yes | Yes | No | Yes | Yes | Yes |
| Drug | Yes | No | No | No | No | Yes |
| Literature | Yes | No | No | No | No | Yes |
| Pathway | Yes | No | No | No | No | Yes |
| Immune | Limited | No | No | No | Yes | No |
| Structural | Yes | No | No | No | No | No |

---

## Appendix C: Clinical Study Report Template Structure

Based on analysis of industry-standard clinical reporting templates (e.g., Domino/Veramed clinical study reporting):

### Directory Structure
```
clinical-study-report/
├── prod/                    # Production programs
│   ├── adam/               # Analysis Data Model datasets
│   │   ├── adam_flows/    # ADaM workflow scripts
│   ├── tfl/               # Tables, Figures, Listings
│   │   └── tfl_flows/     # TFL workflow scripts
├── qc/                     # Quality Control programs
│   ├── adam/               # QC for ADaM datasets
│   │   ├── adam_flows/
│   ├── tfl/               # QC for TFL outputs
│   │   └── tfl_flows/
├── utilities/              # Helper scripts
│   ├── init_datasets_re.py
│   └── import_metadata.sas
├── flows/                  # Pipeline orchestration
│   ├── flow_1.py
│   └── flow_2.py
└── share/                  # Shared resources
    └── macros/            # Reusable SAS macros
```

### Key Components
1. **ADaM Datasets** - Analysis Data Model (CDISC standard)
2. **TFL Outputs** - Tables, Figures, and Listings
3. **QC Pipeline** - PROC COMPARE for data validation
4. **Metadata Management** - Excel-based metadata import
5. **Pipeline Orchestration** - Dependency-aware job execution

### Naming Conventions
- ADaM programs: Named by dataset (e.g., ADSL.sas)
- TFL programs: Prefixed with `t_` (e.g., t_table1.sas)
- QC programs: Mirror production structure

### Quality Standards
- Independent prod/qc program trees
- Automated comparison reports
- DominoStats JSON for dashboard integration
- Version-controlled metadata repository

---

## Appendix D: Recommended Report Sections for Drug Target Assessment

### Standard Target Assessment Report Template

1. **Executive Summary**
   - Target overview and rationale
   - Key findings summary
   - Recommendation (advance/pause/stop)

2. **Target Biology**
   - Gene/protein description
   - Expression pattern
   - Subcellular localization
   - Protein family and domains

3. **Disease Association**
   - Genetic evidence (GWAS, rare variants)
   - Literature evidence
   - Pathway involvement
   - Clinical correlation

4. **Druggability Assessment**
   - Binding site analysis
   - Structural information
   - Known modulators
   - Target class tractability

5. **Evidence Summary**
   - Evidence by type (genetic, genomic, functional, clinical)
   - Evidence strength rating
   - Confidence assessment
   - Knowledge gaps

6. **Safety Considerations**
   - Tissue expression profile
   - Genetic knockout phenotypes
   - Ortholog conservation
   - Essential gene status

7. **Competitive Landscape**
   - Existing programs
   - Clinical trials
   - Patent landscape
   - Publication trends

8. **Recommendations**
   - Validation experiments
   - Biomarker strategy
   - Patient stratification
   - Development path

9. **Appendices**
   - Data sources and versions
   - Statistical methods
   - Supplementary figures
   - Full reference list

---

*Report generated: 2026-06-03*
*Sources: GitHub repositories, API documentation, public platform documentation, industry standards*
